{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:24:55Z","timestamp":1789770295964,"version":"4.0.1"},"reference-count":12,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T00:00:00Z","timestamp":1430265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>Raltegravir was the first licensed integrase inhibitor. Real-life experience is informative and complements trial data. We therefore evaluated raltegravir use in adults in a large HIV treatment centre. From pharmacy and departmental HIV database records, we identified all adults taking \u22651 dose of raltegravir from first availability to the end of November 2012. Data were collected using a standardised case report form. Two hundred and fifteen individuals provided 502 patient-years (median 2.6 years\/person) of raltegravir use. Of 215 individuals, 166 (77%) were male, median age 43 years; 189 (88%) were antiretroviral therapy (ART)-experienced and 26 (12%) ART-naive, with median baseline CD4 counts of 324 and 54 cells\/\u00b5L, respectively. Of ten individuals using once-daily raltegravir, four, with good adherence remained virologically suppressed after a median 28 months, four stopped against medical advice, one stopped to simplify and one failed virologically. In hepatitis co-infection, 35 individuals (92 patient-years) took raltegravir without evidence of hepatotoxicity. Six women started raltegravir during pregnancy for intensification (5\/6) or switch for tolerability without complications. Of ten individuals stopping raltegravir after virological failure, 2\/4 with successful sequencing showed resistance. Raltegravir appears safe and effective, without evidence of toxicity above that in published trials, including in pregnancy and co-infections. Once-daily dosing seems effective where adherence is good.<\/jats:p>","DOI":"10.1177\/0956462415584485","type":"journal-article","created":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T20:01:09Z","timestamp":1430424069000},"page":"387-393","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Five years\u2019 real-life experience with raltegravir in a large HIV centre"],"prefix":"10.1177","volume":"27","author":[{"given":"Clare","family":"van Halsema","sequence":"first","affiliation":[{"name":"Monsall Unit, Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Whitfield","sequence":"additional","affiliation":[{"name":"Monsall Unit, Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Lin","sequence":"additional","affiliation":[{"name":"University of Manchester School of Medicine, Oxford Road, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Ashton","sequence":"additional","affiliation":[{"name":"Monsall Unit, Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Torkington","sequence":"additional","affiliation":[{"name":"Monsall Unit, Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ustianowski","sequence":"additional","affiliation":[{"name":"Monsall Unit, Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,4,29]]},"reference":[{"key":"bibr1-0956462415584485","unstructured":"Merck Sharp & Dohme Limited. Summary of product characteristics Isentress 400\u2009mg film-coated tablets, 2013. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/20484\/SPC\/ (accessed 17 April 2015)."},{"key":"bibr2-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181da1287"},{"key":"bibr3-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70093-8"},{"key":"bibr4-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00636.x"},{"key":"bibr5-0956462415584485","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/hiv.12110","volume":"15","author":"Williams I","year":"2014","journal-title":"HIV Med"},{"key":"bibr6-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1177\/0956462413476275"},{"key":"bibr7-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1179\/1973947812Y.0000000066"},{"key":"bibr8-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2013.0059"},{"key":"bibr9-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1177\/2325957413488176"},{"key":"bibr10-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2011.010469"},{"key":"bibr11-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01030.x"},{"key":"bibr12-0956462415584485","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2011.00971.x"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462415584485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462415584485","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462415584485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:35:01Z","timestamp":1777674901000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462415584485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,29]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1177\/0956462415584485"],"URL":"https:\/\/doi.org\/10.1177\/0956462415584485","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,29]]}}}